Glen Eagle Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-140
| Closed | -$25.6K | – | 1020 |
|
|
2025
Q4 | $25.6K | Sell |
140
-5
| -3% | -$877 | ﹤0.01% | 545 |
|
|
2025
Q3 | $22.2K | Sell |
145
-75
| -34% | -$11.4K | ﹤0.01% | 561 |
|
|
2025
Q2 | $30.7K | Hold |
220
| – | – | ﹤0.01% | 500 |
|
|
2025
Q1 | $32.3K | Sell |
220
-71
| -24% | -$10.3K | 0.01% | 480 |
|
|
2024
Q4 | $38.1K | Hold |
291
| – | – | 0.01% | 460 |
|
|
2024
Q3 | $45.3K | Buy |
291
+4
| +1% | +$646 | 0.01% | 436 |
|
|
2024
Q2 | $44.8K | Buy |
287
+153
| +114% | +$23K | 0.01% | 420 |
|
|
2024
Q1 | $18.1K | Hold |
134
| – | – | ﹤0.01% | 558 |
|
|
2023
Q4 | $18K | Sell |
134
-25
| -16% | -$3.25K | ﹤0.01% | 547 |
|
|
2023
Q3 | $21.5K | Buy |
159
+11
| +7% | +$1.5K | 0.01% | 517 |
|
|
2023
Q2 | $21.1K | Hold |
148
| – | – | ﹤0.01% | 523 |
|
|
2023
Q1 | $20.5K | Sell |
148
-6
| -4% | -$807 | 0.01% | 508 |
|
|
2022
Q4 | $20.8K | Buy |
154
+89
| +137% | +$11.2K | 0.01% | 491 |
|
|
2022
Q3 | $7.13K | Buy |
65
+23
| +55% | +$2.92K | ﹤0.01% | 647 |
|
|
2022
Q2 | $5.48K | Sell |
42
-7
| -14% | -$918 | ﹤0.01% | 704 |
|
|
2022
Q1 | $6.5K | Hold |
49
| – | – | ﹤0.01% | 686 |
|
|
2021
Q4 | $5.71K | Sell |
49
-228
| -82% | -$26.8K | ﹤0.01% | 695 |
|
|
2021
Q3 | $33.2K | Hold |
277
| – | – | 0.01% | 450 |
|
|
2021
Q2 | $33.1K | Hold |
277
| – | – | 0.01% | 452 |
|
|
2021
Q1 | $27.5K | Buy |
277
+135
| +95% | +$13.6K | 0.01% | 455 |
|
|
2020
Q4 | $14.1K | Buy |
142
+17
| +14% | +$1.8K | 0.01% | 563 |
|
|
2020
Q3 | $13.7K | Buy |
125
+25
| +25% | +$2.78K | 0.01% | 531 |
|
|
2020
Q2 | $10.6K | Hold |
100
| – | – | 0.01% | 555 |
|
|
2020
Q1 | $8.93K | Hold |
100
| – | – | 0.01% | 532 |
|
|
2019
Q4 | $9.97K | Hold |
100
| – | – | 0.01% | 585 |
|
|
2019
Q3 | $8.91K | Hold |
100
| – | – | 0.01% | 529 |
|
|
2019
Q2 | $8.26K | Sell |
100
-325
| -76% | -$25.5K | 0.01% | 534 |
|
|
2019
Q1 | $34.4K | Hold |
425
| – | – | 0.03% | 313 |
|
|
2018
Q4 | $32.3K | Hold |
425
| – | – | 0.03% | 293 |
|
|
2018
Q3 | $33.6K | Hold |
425
| – | – | 0.02% | 308 |
|
|
2018
Q2 | $29.8K | Hold |
425
| – | – | 0.02% | 310 |
|
|
2018
Q1 | $29.7K | Hold |
425
| – | – | 0.02% | 301 |
|
|
2017
Q4 | $29.5K | Hold |
425
| – | – | 0.03% | 294 |
|
|
2017
Q3 | $28.8K | Sell |
425
-75
| -15% | -$4.74K | 0.03% | 291 |
|
|
2017
Q2 | $34.1K | Hold |
500
| – | – | 0.03% | 248 |
|
|
2017
Q1 | $31.1K | Hold |
500
| – | – | 0.03% | 246 |
|
|
2016
Q4 | $27.3K | Buy |
+500
| New | +$28.4K | 0.02% | 257 |
|
Other funds holding AZN
IA
VCM
VAM
Glen Eagle Advisors's AZN Position: Q1 2026 in Review
Glen Eagle Advisors sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 140 shares — an estimated $25.6K sold.
Glen Eagle Advisors first reported a position in AZN in Q4 2016 and held it in 37 quarters. The position peaked at $45.3K in Q3 2024. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Glen Eagle Advisors reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
- Glen Eagle Advisors sold 140 AstraZeneca shares in Q1 2026, an estimated $25.6K.
- Glen Eagle Advisors first reported a position in AstraZeneca in Q4 2016 and held it in 37 quarters.
- Glen Eagle Advisors's AstraZeneca position peaked at $45.3K in Q3 2024.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.